[The use of SM-4300 against patients with severe infections complicated with advanced cancer].
Clinical efficacy and safety of SM-4300, a newly developed human immunoglobulin, have been studied in 7 episodes of severe infections complicated with advanced cancer. Clinical effect of SM-4300 was good in 1 case, fair in 5 and poor in 1. The efficacy rate was summarized as 14.35%, and the rate including fair response was 85.7%. No subjective and objective clinical side effect was observed and abnormal laboratory findings were not noted. In conclusion, combination therapy with SM-4300 and antibiotics was considered to be safe and effective against the patients with severe infections complicated with advanced cancer.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000628:therapy*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300